Skip to main content
Premium Trial:

Request an Annual Quote

Cell-based Dx Firm Lophius Biosciences Raises $5.3M

NEW YORK (GenomeWeb News) – T-cell-based diagnostics development firm Lophius Biosciences today announced the closing of a financing round that brought in €4 million ($5.3 million) in funding.

Lophius will use the cash infusion to launch its technologies, it said. VRD and WIC were new investors in the round. Existing investors include S-Refit, HighTech Gründerfonds, Bayern Kapital and two angel investors.

The Regensburg, Germany-based company also announced Ralf Wagner has been named managing director. He will focus on rounding out and launching Lophius' product portfolio. Wagner was founder, CEO, and CSO of GeneArt, which was acquired by Life Technologies in 2010.

Lophius develops T-cell based tests for diagnostic purposes and as possible therapy controls in transplantation, infection, and autoimmune diseases. In 2011, it raised $2 million in a private financing.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.